Why Men Develop Psychosis More Often: What the Research Shows

Psychosis occurs more frequently in men than in women, a finding that holds up consistently across countries, decades of research, and different study designs (Jongsma et al., 2019; Ochoa et al., 2012; Castillejos et al., 2018). This piece walks through the size of that gap, where it comes from biologically and environmentally, how it changes across the lifespan, and what it means for treatment. It also draws a clear line between two terms the general public tends to use interchangeably but that mean genuinely different things: psychosis and schizophrenia.

Ps

ychosis and schizophrenia are not the same thing

This distinction gets lost constantly in everyday conversation, so it's worth spelling out plainly before getting into the numbers.

Psychosis is a symptom state, not a diagnosis on its own. It describes a loss of the capacity to distinguish what is real from what is not, typically involving hallucinations, delusions, or disorganized thinking (Almuqrin et al., 2023; De Marcilla Lappin et al., 2025). Psychosis can show up as a feature of many different conditions: schizophrenia, bipolar disorder during a manic or depressive episode, severe depression, postpartum psychosis, substance-induced states, and even some medical or neurological illnesses. Think of psychosis as a symptom cluster, similar to how "fever" describes a state the body can enter for many different underlying reasons, not a diagnosis in itself.

Schizophrenia, by contrast, is a specific, chronic psychiatric diagnosis. It requires psychotic symptoms to be present for an extended period, generally at least six months under standard diagnostic criteria, alongside other features like negative symptoms, meaning reduced motivation, emotional expression, or social engagement, and a meaningful decline in functioning that isn't better explained by another condition like bipolar disorder or substance use. So the relationship between the two terms is one-directional: schizophrenia always involves psychosis, but psychosis does not always mean someone has schizophrenia. A person having a single psychotic episode triggered by extreme stress, sleep deprivation, or substance use is not the same as a person living with schizophrenia, even though both would be described as experiencing psychosis in that moment.

This distinction matters for the topic of this piece specifically, because the male excess shows up in both categories, and it's worth stating that plainly rather than letting the two blur together: men have a higher incidence of psychosis broadly, and men have a higher incidence of schizophrenia specifically, at almost exactly the same ratio, roughly 1.4 men for every 1 woman, in both cases (Jongsma et al., 2019; Castillejos et al., 2018; Moniem & Kafetzopoulos, 2025; Li et al., 2022; Aleman et al., 2003; Abel et al., 2010). This isn't one broad category driving an illusion of a gap in a narrower one. Both the symptom state and the specific chronic diagnosis independently show the same male-skewed pattern.

The size of the gap

Across all psychotic disorders combined, the male-to-female incidence rate ratio is approximately 1.44, meaning men are diagnosed at roughly 1.4 times the rate of women (Jongsma et al., 2019; Castillejos et al., 2018; Jacinto et al., 2023). That gap is not uniform across diagnoses, though. For non-affective psychoses, a category that includes schizophrenia, the ratio widens to 1.60 (Jongsma et al., 2019; Castillejos et al., 2018; Kirkbride et al., 2006). For schizophrenia specifically, the ratio sits around 1.42 (Aleman et al., 2003; Li et al., 2022; Kirkbride et al., 2006). Affective psychosis, meaning psychotic symptoms occurring alongside a mood disorder like bipolar disorder, actually shows the pattern reversed slightly, with a ratio of 0.87, indicating either roughly equal rates or a mild female preponderance (Jongsma et al., 2019; Castillejos et al., 2018; Kirkbride et al., 2006). Substance-induced psychosis is higher in men across every age band studied (Bogren et al., 2010; Jacinto et al., 2023).

One migration-related finding stands out for how large the gap becomes in a specific population. Among North African immigrants in Europe, the male-to-female risk ratio for non-affective psychotic disorder reaches 5.1, far exceeding the roughly 1.8 ratio seen among non-migrant Europeans (Ven et al., 2016). This suggests migration-related stress interacts with male-specific vulnerability in a way that substantially amplifies the baseline sex gap.

How the gap changes with age

The male excess concentrates heavily in early adulthood, peaking between ages 20 and 29 (Li et al., 2022; Kirkbride et al., 2016; Bogren et al., 2010). On average, men develop their first episode 3.2 to 4.1 years earlier than women (Li et al., 2022; Riecher-Rössler et al., 2018; Bogren et al., 2010). Women, meanwhile, show a bimodal pattern: a first incidence peak between ages 20 and 39, similar to men though later and smaller, and a second, distinct peak during the perimenopausal years (Li et al., 2022; Bogren et al., 2010).

That second peak appears connected to estrogen decline. Estrogen is thought to raise the biological threshold needed to trigger psychosis, effectively buffering women against onset until menopause removes that protection (Pence et al., 2022; Li et al., 2022; Riecher-Rössler et al., 2018). This produces a genuine crossover: a Swedish nationwide registry study confirmed that the male excess in schizophrenia seen at ages 15 to 49 flips into a female excess by ages 60 to 79 (Yang et al., 2024). Despite the male incidence advantage earlier in life, lifetime prevalence of psychotic disorders ends up roughly similar between the sexes overall, precisely because of this later female peak (Moniem & Kafetzopoulos, 2025; Li et al., 2022; Solmi et al., 2023). The male excess is a difference in when psychosis tends to strike, not necessarily in how many people are ultimately affected across a full lifespan.

Why a higher incidence in men doesn't produce a higher lifetime total: the schizophrenia paradox, unpacked

For schizophrenia specifically, the same pattern holds, and the research identifies several distinct reasons the incidence gap doesn't carry through to a lifetime prevalence gap, beyond just the later female incidence peak described above.

One factor is genuinely sobering: men with schizophrenia face substantially higher mortality than women with the condition, driven by both suicide and cardiovascular causes, which narrows the male-female prevalence gap over time simply because a disproportionate share of affected men die earlier (Sommer et al., 2020). In other words, part of why the sexes end up looking similar in lifetime prevalence counts is not that men are somehow catching up to a healthier equilibrium, it's that men with schizophrenia are dying at a higher rate, which mechanically shrinks how many are still alive to be counted in prevalence data at any later point.

A second factor is historical rather than current: diagnostic criteria used before the DSM-III-R revision were more restrictive in ways that tended to exclude women who would meet modern criteria, artificially narrowing the apparent gap in older data (Ochoa et al., 2012; Longenecker et al., 2010). This matters as a caution about older studies, though it's worth being precise here: even under modern, less restrictive diagnostic criteria, the male incidence excess persists (Ochoa et al., 2012; Longenecker et al., 2010), so diagnostic bias explains some historical measurement noise, not the underlying pattern itself.

A third factor echoes what shows up in the broader psychosis literature: women with schizophrenia more often present with affective symptoms and better-preserved social functioning than men do, a presentation pattern that leads to misdiagnosis and delayed detection in a meaningful number of cases (Ferrara et al., 2023; Sommer et al., 2020). And as with psychosis broadly, men with schizophrenia show substantially higher rates of cannabis and alcohol use, which is linked to earlier onset and a more severe overall illness course (Ochoa et al., 2012; Sommer et al., 2020; Abel et al., 2010; Räsänen et al., 2000).

What's driving the difference

Biological and developmental factors

Several converging lines of evidence point to earlier neurodevelopment as part of the explanation. The male brain matures more slowly than the female brain during prenatal and perinatal periods, particularly in the early-developing right hemisphere, which extends the window during which environmental stressors and toxins can do damage (Schore, 2017). In animal models, a prenatal immune challenge, meant to simulate infection during pregnancy, produces sex-dependent effects: male offspring show more pronounced abnormalities in brain immune cells and elevated inflammatory gene activity, along with schizophrenia-like sensory processing deficits (Hui et al., 2018).

Hormones play a role on both sides of the sex difference. In women, estrogen's neuroprotective effect appears to delay onset and reduce severity until menopause (Murray et al., 2017; Riecher-Rössler, 2016). In men, disruptions to how testosterone shapes brain circuits connecting the frontal cortex and striatum during adolescence may help explain why negative symptoms, the more withdrawal- and motivation-related symptoms of psychosis, are more common in males (Barendse et al., 2023). Some studies also find testosterone deficiency in men with schizophrenia-spectrum psychosis, even before treatment begins, though whether this is a cause of the illness or a consequence of it remains genuinely unresolved (Riecher-Rössler, 2016; Matuszewska et al., 2023).

Genetic risk also appears to weigh more heavily in men. Polygenic risk scores, which aggregate many small genetic variants associated with schizophrenia, bipolar disorder, and major depression, explain significantly more of the variation in psychosis risk among men than among women (Mitjans et al., 2024), suggesting men may need less environmental push to reach the same threshold of illness.

Stress, environment, and substance use

Psychosocial stress activates the body's stress response system, and that activation appears to interact with dopamine signaling in a way that's central to psychosis (Holtzman et al., 2013; Xenaki et al., 2023). Early exposure to stress can sensitize a person to future stress, amplifying that dopamine response over time and pushing genetically vulnerable individuals, more often men, over the threshold into psychosis (Holtzman et al., 2013; Xenaki et al., 2023). Childhood adversity in men has specifically been linked to an interacting cluster of substance misuse, violence involvement, and high-risk sexual behavior that together predict psychotic outcomes (Zhang & Coid, 2023). Physical and emotional childhood neglect is also more commonly reported by male patients and predicts more severe negative symptoms and worse long-term functioning (Pruessner et al., 2019).

Environmental exposures more broadly show a male-skewed pattern. Urban upbringing and migration are both more strongly linked to psychosis risk in men than in women (Pence et al., 2022; Khan et al., 2026). Substance use, particularly cannabis, cocaine, and alcohol, is more common among men with psychosis and may independently raise incidence (Ochoa et al., 2012). Cannabis appears to stimulate dopamine signaling directly, and heavy use starting in early adolescence carries the highest risk (Rawani et al., 2024; Xenaki et al., 2023).

A caveat worth naming directly

Part of the incidence gap may not be a true biological difference at all, but a detection difference. Women more often present with affective and atypical symptoms rather than the classic hallucinations and delusions clinicians are trained to look for first, which appears to lead to underdiagnosis and delayed treatment in women specifically (Carter et al., 2022; Barajas et al., 2015). This doesn't erase the male excess, which shows up too consistently across too many study designs to be explained by detection bias alone, but it does mean the true gap may be somewhat smaller than the raw incidence numbers suggest.

Men are consistently under-diagnosed for mood disorders and seek professional mental health help far less than women, a pattern that holds across race, age, and social class (Smith & Hebdon, 2023; Möller-Leimkühler, 2002; Wendt & Shafer, 2016). Controlling for actual prevalence, women in the United States are 1.6 times more likely than men to receive mental health treatment, and men with depression are only half as likely to ever start psychotherapy (Sagar-Ouriaghli et al., 2019; Eggenberger et al., 2021). Part of this gap is diagnostic rather than behavioral: men tend to express depression through externalizing symptoms like irritability and alcohol use rather than the criteria standard diagnostic tools were built around, and men "omit" symptoms and require greater underlying severity before reporting them at all, meaning real depression is systematically missed even when men are sitting in front of a clinician (Sagar-Ouriaghli et al., 2019; Shi et al., 2021). A meta-analysis spanning 35 samples found that stronger endorsement of traditional masculine norms, stoicism, self-reliance, emotional control, correlates significantly with both negative attitudes toward seeking help and higher self-stigma about needing it (Üzümçeker, 2025), and men with the highest adherence to those norms typically don't engage psychotherapy until symptoms reach a crisis point (Eggenberger et al., 2021). The consequence of this compounding gap is severe: men die by suicide at more than three times the rate of women, are less likely to mention suicidal thoughts before acting on them, and attitudinal barriers, not access or cost, are the strongest predictor of whether a symptomatic man ever seeks help at all (Smith & Hebdon, 2023; Shi et al., 2021; Rice et al., 2020).

Early risk and the path toward diagnosis

Among people already identified as being at clinical high risk for psychosis, men convert to full psychosis at meaningfully higher rates than women, 20.6% versus 17.5% at two years, and 24.3% versus 19.9% at three years of follow-up (He et al., 2023). Men at high risk also tend to show more pronounced negative symptoms, higher rates of past substance use, and greater difficulty with social functioning compared to women in the same risk category (Rietschel et al., 2017; Barajas et al., 2015).

What this means for treatment

Sex differences in psychosis don't stop at who gets diagnosed, they extend into which treatments work best. In the BeSt InTro randomized trial, amisulpride produced a faster reduction in psychotic symptoms in men than in women, and outperformed both aripiprazole and olanzapine on symptom severity specifically in male patients, with no such advantage found in women (Hoekstra et al., 2021). Notably, amisulpride didn't cause more side effects in men, while women on the same drug experienced significantly higher prolactin elevation and weight gain, likely explained by women having roughly 72% higher blood levels of the drug at the same dose (Hoekstra et al., 2021).

Long-acting injectable antipsychotics, which are administered periodically rather than taken as a daily pill, show a particular advantage for men, who have higher documented rates of substance use and medication non-adherence (Pelizza et al., 2025; Mustonen et al., 2025). Formulations like paliperidone and aripiprazole injectables have shown meaningfully lower relapse and hospitalization risk compared to oral antipsychotics in early psychosis (Hamina et al., 2024; Lian et al., 2021, 2022).

Combining antipsychotic medication with cognitive behavioral therapy for psychosis (CBTp) outperforms either treatment alone. A pooled analysis of two randomized trials found the combination produced significantly better symptom scores and recovery outcomes than antipsychotics by themselves (Morrison et al., 2025). For patients admitted to inpatient care, Acceptance and Commitment Therapy delivered during the hospital stay reduced psychotic symptoms and cut the risk of rehospitalization within four months by roughly 3.76-fold compared to supportive therapy alone (Gaudiano et al., 2023; Zoromba et al., 2024).

Early intervention services, coordinated programs that combine medication, therapy, and case management soon after a first episode, reduce treatment discontinuation by about 30% and psychiatric hospitalization by about 26% compared to standard care (Correll et al., 2018). Men entering these programs tend to have a higher rate of schizophrenia-spectrum diagnoses, more substance use, and lower functional remission at two years compared to women in the same programs (56.1% vs. 43.8% schizophrenia-spectrum diagnoses; 39.0% vs. 49.2% functional remission), which is part of why treatment approaches suited to substance use and adherence challenges, like long-acting injectables, matter disproportionately for male patients (Pelizza et al., 2025).

Key takeaways

• Psychosis and schizophrenia are not interchangeable terms. Psychosis is a symptom state, a loss of contact with reality, that can occur in many different conditions. Schizophrenia is one specific, chronic diagnosis that requires psychotic symptoms plus other features, like negative symptoms and functional decline, persisting over an extended period.

• Men show a higher incidence of both psychosis broadly and schizophrenia specifically, at almost the same ratio in each case, roughly 1.4 men for every 1 woman.

• Men are diagnosed with psychosis at roughly 1.4 times the rate of women overall, and the gap is widest specifically for non-affective psychoses like schizophrenia.

• Affective psychosis, tied to mood disorders like bipolar disorder, doesn't follow this pattern and shows roughly equal or slightly female-skewed rates.

• Men typically develop their first episode 3 to 4 years earlier than women.

• Women show a second incidence peak around menopause, tied to declining estrogen, which is thought to have a protective effect against psychosis earlier in life.

• Because of that later female peak, lifetime prevalence ends up roughly similar between men and women, even though incidence at any given age differs sharply.

• For schizophrenia specifically, the incidence-to-prevalence gap closing isn't only about the later female peak. Higher mortality among men with schizophrenia, from both suicide and cardiovascular causes, also mechanically narrows the prevalence gap over time.

• The causes are not singular. Slower prenatal brain maturation, hormonal differences, higher genetic loading, and greater sensitivity to environmental stressors like urban upbringing, migration, and substance use all appear to contribute in men specifically.

• Some of the apparent gap may reflect underdiagnosis in women, since women more often present with atypical or mood-related symptoms that get missed by diagnostic criteria built around classic presentations, both in psychosis generally and schizophrenia specifically.

• Treatment response can differ by sex. Amisulpride shows a specific advantage in men, and long-acting injectable medications are particularly useful for men given documented higher rates of non-adherence and substance use.

• Combining medication with therapy, especially CBT for psychosis or Acceptance and Commitment Therapy, consistently outperforms medication alone.

• Early intervention, meaning fast, coordinated treatment after a first episode, meaningfully improves outcomes regardless of sex.

A note on using this information

This piece is a synthesis of published research intended for general education, not medical advice, and it is not a tool for diagnosing yourself or anyone else. Psychosis is a serious, treatable condition, and both the biological mechanisms and treatment approaches described here are the subject of ongoing research, not settled fact in every detail. If you or someone you know is showing signs of psychosis, hearing or seeing things others don't, holding fixed beliefs that don't match reality, or a sudden, significant change in thinking or behavior, that warrants evaluation by a licensed clinician as soon as possible. If there is any immediate risk to someone's safety or life, contact emergency services right away rather than waiting for a scheduled appointment.

References

Abel, K., Drake, R., & Goldstein, J. (2010). Sex differences in schizophrenia. International Review of Psychiatry, 22, 417-428. https://doi.org/10.3109/09540261.2010.515205

Aleman, A., Kahn, R., & Selten, J. (2003). Sex differences in the risk of schizophrenia: Evidence from meta-analysis. Archives of General Psychiatry, 60(6), 565-571. https://doi.org/10.1001/archpsyc.60.6.565

Ansari, S. A., Khan, F. I., Alshanberi, A., Alam, M. Z., Saboor, M., & Ashraf, G. (2026). Gender-specific perspectives in schizophrenia: Recent advances and future directions. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 111617. https://doi.org/10.1016/j.pnpbp.2026.111617

Barajas, A., Ochoa, S., Obiols, J., & Lalucat-Jo, L. (2015). Gender differences in individuals at high-risk of psychosis: A comprehensive literature review. The Scientific World Journal, 2015. https://doi.org/10.1155/2015/430735

Barendse, M., Lara, G. A., Guyer, A. E., Swartz, J. R., Taylor, S. L., Shirtcliff, E. A., & Tully, L. M. (2023). Sex and pubertal influences on the neurodevelopmental underpinnings of schizophrenia: A case for longitudinal research on adolescents. Schizophrenia Research, 252, 231-241. https://doi.org/10.1016/j.schres.2022.12.011

Bogren, M., Mattisson, C., Isberg, P., Munk-Jørgensen, P., & Nettelbladt, P. (2010). Incidence of psychotic disorders in the 50 year follow up of the Lundby population. Australian and New Zealand Journal of Psychiatry, 44, 31-39. https://doi.org/10.3109/00048670903393647

Carter, B., Wootten, J., Archie, S., Terry, A., & Anderson, K. (2022). Sex and gender differences in symptoms of early psychosis: A systematic review and meta-analysis. Archives of Women's Mental Health, 25, 679-691. https://doi.org/10.1007/s00737-022-01247-3

Castillejos, M., Martín-Pérez, C., & Moreno-Küstner, B. (2018). A systematic review and meta-analysis of the incidence of psychotic disorders: The distribution of rates and the influence of gender, urbanicity, immigration and socio-economic level. Psychological Medicine, 48, 2101-2115. https://doi.org/10.1017/s0033291718000235

Correll, C., Galling, B., Pawar, A., Krivko, A., Bonetto, C., Ruggeri, M., Craig, T., Nordentoft, M., Srihari, V., Guloksuz, S., Hui, C., Chen, E., Valencia, M., Juárez, F., Robinson, D., Schooler, N., Brunette, M., Mueser, K., Rosenheck, R., & Kane, J. (2018). Comparison of early intervention services vs treatment as usual for early-phase psychosis: A systematic review, meta-analysis, and meta-regression. JAMA Psychiatry, 75, 555-565. https://doi.org/10.1001/jamapsychiatry.2018.0623

Eggenberger, L., Fordschmid, C., Ludwig, C. M., Weber, S., Grub, J., Komlenac, N., & Walther, A. (2021). Men's psychotherapy use, male role norms, and male-typical depression symptoms: Examining 716 men and women experiencing psychological distress. Behavioral Sciences, 11. https://doi.org/10.3390/bs11060083

Falkenburg, J., & Tracy, D. (2014). Sex and schizophrenia: A review of gender differences. Psychosis, 6, 61-69. https://doi.org/10.1080/17522439.2012.733405

Ferrara, M., Curtarello, E. M., Gentili, E., Domenicano, I., Vecchioni, L., Zese, R., Alberti, M., Franchini, G., Sorio, C., Benini, L., Little, J., Carozza, P., Dazzan, P., & Grassi, L. (2023). Sex differences in schizophrenia-spectrum diagnoses: Results from a 30-year health record registry. Archives of Women's Mental Health, 27, 11-20. https://doi.org/10.1007/s00737-023-01371-8

Gaudiano, B., Ellenberg, S., Johnson, J. E., Mueser, K., & Miller, I. W. (2023). Effectiveness of Acceptance and Commitment Therapy for inpatients with psychosis: Implementation feasibility and acceptability from a pilot randomized controlled trial. Schizophrenia Research, 261, 72-79. https://doi.org/10.1016/j.schres.2023.09.017

Hamina, A., Taipale, H., Lieslehto, J., Lähteenvuo, M., Tanskanen, A., Mittendorfer-Rutz, E., & Tiihonen, J. (2024). Comparative effectiveness of antipsychotics in patients with schizophrenia spectrum disorder. JAMA Network Open, 7. https://doi.org/10.1001/jamanetworkopen.2024.38358

He, X.-Y., Wang, S., Hou, C., Guo, L., Huang, Z., Zhao, Q.-N., & Li, D. (2023). Meta-analysis of gender differences in transition prevalence among individuals at clinical high risk of psychosis. Asian Journal of Psychiatry, 86, 103639. https://doi.org/10.1016/j.ajp.2023.103639

Hoekstra, S., Bartz-Johannessen, C., Sinkeviciute, I., Reitan, S., Kroken, R., Løberg, E., Larsen, T., Rettenbacher, M., Johnsen, E., & Sommer, I. (2021). Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: Results from the BeSt InTro study. NPJ Schizophrenia, 7. https://doi.org/10.1038/s41537-021-00170-3

Holtzman, C. W., Trotman, H., Goulding, S. M., Ryan, A. T., Macdonald, A. N., Shapiro, D. I., Brasfield, J., & Walker, E. F. (2013). Stress and neurodevelopmental processes in the emergence of psychosis. Neuroscience, 249, 172-191. https://doi.org/10.1016/j.neuroscience.2012.12.017

Hui, C., St-Pierre, A., Hajj, H. E., Remy, Y., Hébert, S. S., Luheshi, G., Srivastava, L., & Tremblay, M. (2018). Prenatal immune challenge in mice leads to partly sex-dependent behavioral, microglial, and molecular abnormalities associated with schizophrenia. Frontiers in Molecular Neuroscience, 11. https://doi.org/10.3389/fnmol.2018.00013

Jacinto, R., Ding, T., Stafford, J., Baio, G., & Kirkbride, J. (2023). The incidence of psychotic disorders in the Republic of Ireland: A systematic review. Irish Journal of Psychological Medicine, 41, 362-374. https://doi.org/10.1017/ipm.2023.35

Jongsma, H., Turner, C., Kirkbride, J., & Jones, P. B. (2019). International incidence of psychotic disorders, 2002-17: A systematic review and meta-analysis. The Lancet Public Health, 4, e229-e244. https://doi.org/10.1016/s2468-2667(19)30056-8

Khan, J. A., Edwards, J., Le, B., Lizotte, D., & Anderson, K. K. (2026). Sex-specific drivers of non-affective psychotic disorders within migrant groups: A 25-year retrospective cohort study of 2 million migrants. Social Psychiatry and Psychiatric Epidemiology. https://doi.org/10.1007/s00127-026-03152-x

Kirkbride, J. B., Hameed, Y., Ankireddypalli, G., Ioannidis, K., Crane, C., Nasir, M., Kabacs, N., Metastasio, A., Jenkins, O. T., Espandian, A., Spyridi, S., Ralevic, D., Siddabattuni, S., Walden, B., Adeoye, A., Perez, J., & Jones, P. B. (2016). The epidemiology of first episode psychosis in early intervention in psychosis services: Findings from the Social Epidemiology of Psychoses in East Anglia (SEPEA) study. American Journal of Psychiatry, 174, 143-153. https://doi.org/10.1176/appi.ajp.2016.16010103

Kirkbride, J., Fearon, P., Morgan, C., Dazzan, P., Morgan, K., Tarrant, J., Lloyd, T., Holloway, J., Hutchinson, G., Leff, J., Mallett, R., Harrison, G., Murray, R., & Jones, P. B. (2006). Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: Findings from the 3-center AeSOP study. Archives of General Psychiatry, 63(3), 250-258. https://doi.org/10.1001/archpsyc.63.3.250

Li, X., Zhou, W., & Yi, Z. (2022). A glimpse of gender differences in schizophrenia. General Psychiatry, 35. https://doi.org/10.1136/gpsych-2022-100823

Lian, L., Kim, D. D., Procyshyn, R., Cázares, D., Honer, W., & Barr, A. (2022). Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. PLoS ONE, 17. https://doi.org/10.1371/journal.pone.0267808

Lian, L., Kim, D. D., Procyshyn, R., Fredrikson, D., Cázares, D., Honer, W., & Barr, A. (2021). Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis. Early Intervention in Psychiatry, 16, 589-599. https://doi.org/10.1111/eip.13202

Longenecker, J. M., Genderson, J., Dickinson, D., Malley, J., Elvevåg, B., Weinberger, D., & Gold, J. (2010). Where have all the women gone? Participant gender in epidemiological and non-epidemiological research of schizophrenia. Schizophrenia Research, 119, 240-245. https://doi.org/10.1016/j.schres.2010.03.023

Matuszewska, A., Kowalski, K., Jawień, P., Tomkalski, T., Gaweł-Dąbrowska, D., Merwid-Ląd, A., Szeląg, E., Błaszczak, K., Wiatrak, B., Danielewski, M., Piasny, J., & Szeląg, A. (2023). The hypothalamic-pituitary-gonadal axis in men with schizophrenia. International Journal of Molecular Sciences, 24. https://doi.org/10.3390/ijms24076492

Mitjans, M., Papiol, S., Fernández-Vilas, M., Nas, J. G. A., Acosta-Díez, M., López-Lera, M. Z., Costas, J., Arango, C., Vilella, E., Martorell, L., Bobes, J., Crespo-Facorro, B., González-Pinto, A., & Rosa, A. (2024). Shared vulnerability and sex-dependent polygenic burden in psychotic disorders. European Neuropsychopharmacology, 86, 49-54. https://doi.org/10.1016/j.euroneuro.2024.04.017

Möller-Leimkühler, A. (2002). Barriers to help-seeking by men: A review of sociocultural and clinical literature with particular reference to depression. Journal of Affective Disorders, 71(1-3), 1-9. https://doi.org/10.1016/s0165-0327(01)00379-2

Moniem, I., & Kafetzopoulos, V. (2025). Sex differences in schizophrenia: Symptomatology, treatment efficacy and adverse effects. Frontiers in Psychiatry, 16. https://doi.org/10.3389/fpsyt.2025.1594334

Morrison, A. P., Pyle, M., Law, H., Emsley, R., MacLennan, G., & Hudson, J. (2025). Relative effectiveness of cognitive behavior therapy, antipsychotics and the combination for people with first episode psychosis: A two-study pooled analysis of individual participant data. Schizophrenia Bulletin, 52. https://doi.org/10.1093/schbul/sbaf121

Murray, R., Bhavsar, V., Tripoli, G., & Howes, O. (2017). 30 years on: How the neurodevelopmental hypothesis of schizophrenia morphed into the developmental risk factor model of psychosis. Schizophrenia Bulletin, 43, 1190-1196. https://doi.org/10.1093/schbul/sbx121

Mustonen, A., Taipale, H., Denissoff, A., Ellilä, V., Di Forti, M., Tanskanen, A., Mittendorfer-Rutz, E., Tiihonen, J., & Niemelä, S. (2025). Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis. British Journal of Psychiatry, 228, 317-323. https://doi.org/10.1192/bjp.2025.72

Ochoa, S., Usall, J., Cobo, J., Labad, X., & Kulkarni, J. (2012). Gender differences in schizophrenia and first-episode psychosis: A comprehensive literature review. Schizophrenia Research and Treatment, 2012. https://doi.org/10.1155/2012/916198

Pelizza, L., Ricci, C., Leuci, E., Quattrone, E., Palmisano, D., Pupo, S., Paulillo, G., Pellegrini, C., Pellegrini, P., & Menchetti, M. (2025). Sex comparisons on the beneficial effects of an early intervention program in a patients' cohort with first episode psychosis: What effectiveness in women? Archives of Women's Mental Health, 28, 1151-1166. https://doi.org/10.1007/s00737-025-01566-1

Pence, A. Y., Pries, L., Ferrara, M., Rutten, B., Van Os, J., & Guloksuz, S. (2022). Gender differences in the association between environment and psychosis. Schizophrenia Research, 243, 120-137. https://doi.org/10.1016/j.schres.2022.02.039

Pruessner, M., King, S., Vracotas, N., Abadi, S., Iyer, S., Malla, A., Shah, J., & Joober, R. (2019). Gender differences in childhood trauma in first episode psychosis: Association with symptom severity over two years. Schizophrenia Research, 205, 30-37. https://doi.org/10.1016/j.schres.2018.06.043

Räsänen, S., Pakaslahti, A., Syvälahti, E., Jones, P. B., & Isohanni, M. (2000). Sex differences in schizophrenia: A review. Nordic Journal of Psychiatry, 54, 37-45. https://doi.org/10.1080/080394800427564

Rawani, N. S., Chan, A. W., Dursun, S., & Baker, G. B. (2024). The underlying neurobiological mechanisms of psychosis: Focus on neurotransmission dysregulation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. Antioxidants, 13. https://doi.org/10.3390/antiox13060709

Rice, S., Oliffe, J., Kealy, D., Seidler, Z., & Ogrodniczuk, J. (2020). Men's help-seeking for depression: Attitudinal and structural barriers in symptomatic men. Journal of Primary Care & Community Health, 11. https://doi.org/10.1177/2150132720921686

Riecher-Rössler, A. (2016). Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. The Lancet Psychiatry, 4(1), 63-72. https://doi.org/10.1016/s2215-0366(16)30379-0

Riecher-Rössler, A., Butler, S., & Kulkarni, J. (2018). Sex and gender differences in schizophrenic psychoses: A critical review. Archives of Women's Mental Health, 21, 627-648. https://doi.org/10.1007/s00737-018-0847-9

Rietschel, L., Lambert, M., Karow, A., Zink, M., Müller, H., Heinz, A., De Millas, W., Janssen, B., Gaebel, W., Schneider, F., Naber, D., Juckel, G., Krüger-Özgürdal, S., Wobrock, T., Wagner, M., Maier, W., Klosterkötter, J., & Bechdolf, A. (2017). Clinical high risk for psychosis: Gender differences in symptoms and social functioning. Early Intervention in Psychiatry, 11. https://doi.org/10.1111/eip.12240

Sagar-Ouriaghli, I., Godfrey, E., Bridge, L., Meade, L., & Brown, J. S. L. (2019). Improving mental health service utilization among men: A systematic review and synthesis of behavior change techniques within interventions targeting help-seeking. American Journal of Men's Health, 13. https://doi.org/10.1177/1557988319857009

Schore, A. (2017). All our sons: The developmental neurobiology and neuroendocrinology of boys at risk. Infant Mental Health Journal, 38(1), 15-52. https://doi.org/10.1002/imhj.21616

Shi, P., Yang, A., Zhao, Q., Chen, Z., Ren, X., & Dai, Q. (2021). A hypothesis of gender differences in self-reporting symptom of depression: Implications to solve under-diagnosis and under-treatment of depression in males. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.589687

Smith, G., & Hebdon, M. (2023). Mental health help-seeking behaviour in men. Journal of Advanced Nursing. https://doi.org/10.1111/jan.15869

Solmi, M., Seitidis, G., Mavridis, D., Correll, C., Dragioti, E., Guimond, S., Tuominen, L., Dargél, A., Carvalho, A., Fornaro, M., Maes, M., Monaco, F., Song, M., Shin, I. J., & Cortese, S. (2023). Incidence, prevalence, and global burden of schizophrenia: Data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Molecular Psychiatry, 28, 5319-5327. https://doi.org/10.1038/s41380-023-02138-4

Sommer, I., Tiihonen, J., Van Mourik, A. V., Tanskanen, A., & Taipale, H. (2020). The clinical course of schizophrenia in women and men: A nation-wide cohort study. NPJ Schizophrenia, 6. https://doi.org/10.1038/s41537-020-0102-z

Üzümçeker, E. (2025). Traditional masculinity and men's psychological help-seeking: A meta-analysis. International Journal of Psychology, 60(2), e70031. https://doi.org/10.1002/ijop.70031

Ven, E. V. D., Veling, W., Tortelli, A., Tarricone, I., Berardi, D., Bourque, F., & Selten, J. (2016). Evidence of an excessive gender gap in the risk of psychotic disorder among North African immigrants in Europe: A systematic review and meta-analysis. Social Psychiatry and Psychiatric Epidemiology, 51, 1603-1613. https://doi.org/10.1007/s00127-016-1261-0

Wendt, D., & Shafer, K. (2016). Gender and attitudes about mental health help seeking: Results from national data. Health & Social Work, 41. https://doi.org/10.1093/hsw/hlv089

Werf, M. V. D., Hanssen, M., Köhler, S., Verkaaik, M., Verhey, F., Winkel, R., Os, J. V., & Allardyce, J. (2012). Systematic review and collaborative recalculation of 133,693 incident cases of schizophrenia. Psychological Medicine, 44, 9-16. https://doi.org/10.1017/s0033291712002796

Xenaki, L.-A., Dimitrakopoulos, S., Selakovic, M., & Stefanis, N. (2023). Stress, environment and early psychosis. Current Neuropharmacology, 22, 437-460. https://doi.org/10.2174/1570159x21666230817153631

Yang, Y., Fang, F., Arnberg, F. K., Kuja-Halkola, R., D'Onofrio, B. M., Larsson, H., Brikell, I., Chang, Z., Andreassen, O. A., Lichtenstein, P., Valdimarsdóttir, U., & Lu, D. (2024). Sex differences in clinically diagnosed psychiatric disorders over the lifespan: A nationwide register-based study in Sweden. The Lancet Regional Health - Europe, 47. https://doi.org/10.1016/j.lanepe.2024.101105

Zhang, Y., & Coid, J. (2023). Childhood adversity determines the syndemic effects of violence, substance misuse, and sexual behavior on psychotic spectrum disorder among men. Schizophrenia Bulletin, 50, 684-694. https://doi.org/10.1093/schbul/sbad165

Zoromba, M., Sefouhi, L., Alenezi, A., Selim, A., Awad, S., El-Gazar, H., & El-Monshed, A. (2024). Effectiveness of Acceptance and Commitment Therapy on psychotic severity among inpatients with primary psychoses: A randomized controlled trial. International Journal of Mental Health Nursing. https://doi.org/10.1111/inm.13388